Streetbeat News

Regulatory

CAT

Caterpillar's CEO reported in a conference call that overall demand for the company's products and services remains healthy across most end markets. However, there is some softening in economic conditions in the Asia Pacific region, excluding China.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:49 pm

CENN

Cenntro Electric Group Limited (NASDAQ:CENN) shareholders have approved a scheme to redomicile the company from Australia to the United States, becoming a wholly owned subsidiary of a new U.S. entity, Cenntro Inc., incorporated in Nevada. The scheme, subject to court approval and other conditions, is expected to be implemented on February 27, 2024. This move is aimed at advancing Cenntro's position in the electric vehicle market.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:37 pm

SUPN

Supernus Pharmaceuticals (SUPN) won a court case against Torrent Pharmaceuticals and its subsidiary, confirming the infringement and validity of patents related to Trokendi XR. The U.S. District Court for the District of New Jersey ruled that Torrent's submission of an ANDA to the FDA for a generic version of Trokendi XR infringed on Supernus' patents.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:37 pm

ARCT

Arcturus Therapeutics announced new results for its sa-mRNA COVID-19 vaccine, showing superior immunogenicity to the Omicron BA.4/5 variant and a longer duration of immune response compared to first-generation mRNA vaccines. This follows the vaccine's approval in Japan in November 2023.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:32 pm

CLEU

China Liberal Education Holdings Limited (CLEU), a provider of smart campus solutions and educational services in China, has regained compliance with Nasdaq's minimum bid price requirement. The company received a notification from Nasdaq on February 2, 2024, confirming compliance after a share consolidation increased the bid price above $1.00 per share for 10 consecutive days. The issue of non-compliance was initially raised on September 26, 2023, due to the bid price falling below $1.00 for 30 consecutive days.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:18 pm

BABA

NXPL

NextPlat Corp has received initial approvals to launch an OPKO Health-branded storefront on Alibaba's Tmall Global platform in China, aiming to sell up to 40 health and wellness products. This move, part of an exclusive joint e-commerce development agreement with OPKO Health Europe, a subsidiary of OPKO Health, Inc., marks a strategic milestone for NextPlat in tapping into the global health and wellness market. The company plans to expand its offerings and is awaiting final Chinese regulatory approval to include veterinary and animal health products. The initiative is expected to create a new international e-commerce revenue stream for NextPlat and is supported by local online specialists and Tmall Global-preferred merchant partners.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:13 pm

OCUP

Ocuphire Pharma, Inc. (NASDAQ:OCUP) presented clinical data from its ZETA-1 trial on APX3330 for diabetic retinopathy at the 21st Annual Angiogenesis, Exudation, and Degeneration 2024 Conference. The trial showed a reduction in disease worsening with 24 weeks of APX3330 treatment. Ocuphire plans to finalize the Phase 3 program protocol with the FDA, highlighting APX3330's potential as an oral treatment option for non-proliferative diabetic retinopathy.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:06 pm

CANO

CHEA

FDMT

4D Molecular Therapeutics, Inc. (FDMT) shares rose by 20.1% in pre-market trading after presenting favorable interim data from a Phase 2 clinical trial. Other stocks also moved significantly in pre-market trading, with notable gainers including Chenghe Acquisition Co. (CHEA), Tritium DCFC Limited (DCFC), and YanGuFang International Group Co., Ltd. (YGF). Losers included Cano Health, Inc. (CANO), DMK Pharmaceuticals Corporation (DMK), and NanoString Technologies, Inc. (NSTG), all experiencing significant drops due to various challenges such as bankruptcy proceedings and delisting notices.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 1:04 pm

VNDA

Vanda Pharmaceuticals announced an FDA update regarding the supplemental New Drug Application (NDA) for HETLIOZ in the treatment of insomnia. This development is crucial for the company as it seeks to expand the indications for HETLIOZ, potentially broadening its market and therapeutic reach.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:03 pm

INSE

Inspired Entertainment, Inc. (INSE) has received approval from Nasdaq for its compliance plan to file the overdue Form 10-Q for Q3 2023 by February 28, 2024. The company is also working on filing restated financial statements for 2022 and the first two quarters of 2023 by the same deadline.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:01 pm